Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
The week of 15 October is headlined by two of the market's biggest names. NFLX reports Monday 20 October after the close. TSLA follows on Tuesday 21 October. German car registration data tracked by ORTEX Alt Data is running 269% above the same quarter last year, a dataset that leads Tesla revenue by 43 days with a strong historical fit. That is where the data is pointing so far, not a forecast of the print. GM also reports on 20 October, with the same German data running 133% above last year. Semiconductor giant LRCX rounds out Tuesday's card. Options positioning is sharpening around all four names ahead of their prints.
Bears pushed CHWY short interest to 92.2% of free float, up 25.6 points in a week. WOLF stays at 86.4%, with zero shares left to borrow. On the analyst side, Morgan Stanley lifted CVX to Buy with a $226 target. The bank trimmed its target on BAC from $67 to $61. BLK drew the largest absolute upgrade of the day. GOOGL made news by rolling out a universal shopping cart across Google Search and Gemini, a product move that landed as high-impact today.
ASTS SpaceMobile and IREN saw MSCI World deletion odds jump to 95% and 96% overnight, with the 19 October rank date now four sessions away. Implied forced selling stands at $674M and $635M respectively. On the Russell 2000, KRYS and UMBF each sit exactly on the exit line, with a combined $2.5B of potential forced selling at stake. The CPRT tender for ACVA carries 93% completion odds and would remove ACVA from the Russell 2000, triggering an estimated $243M of index selling.
UK manufacturing hit an all-time August high of 102.3, the strongest reading since records began in 1948. Euro-area industrial production fell to 97.5, its weakest August in five years, and has now dropped for three straight months. The contrast sharpens the divergence between the UK and its continental neighbours heading into year end.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.